Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.64 |
| ▸ | CTSK | P43235 | 7/20 | 0.64 |
| ▸ | CTSB | P07858 | 3/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 2/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473855 | 1.00 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL793015 | 0.90 | BCL2 (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7618822 | 0.89 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6578977 | 0.89 | CTSS (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7433158 | 0.89 | CTSS (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL2173588 | 0.89 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL4420859 | 0.89 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL19493093 | 0.88 | CTSS (0.51) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL2328016 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL17742678 | 0.86 | CTSS (0.67) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2113513-B1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-1577323-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1730128-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| CN-1761680-A | Metastin derivative and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-04-19 | — | — | CN | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | CTSS 2542/4885CTSK 1072/4885CTSB 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.